Viridian Therapeutics, Inc.

NASDAQ (USD): Viridian Therapeutics, Inc. (VRDN)

Last Price

20.19

Today's Change

+0.43 (2.17%)

Day's Change

19.76 - 20.51

Trading Volume

1,616,164

Overview

Market Cap

1 Billion

Shares Outstanding

79 Million

Avg Volume

1,236,625

Avg Price (50 Days)

21.11

Avg Price (200 Days)

17.36

PE Ratio

-4.67

EPS

-4.32

Earnings Announcement

25-Feb-2025

Previous Close

19.76

Open

19.88

Day's Range

19.76 - 20.51

Year Range

11.4 - 27.2

Trading Volume

1,612,096

Price Change Highlight

1 Day Change

2.18%

5 Day Change

4.45%

1 Month Change

1.15%

3 Month Change

-15.59%

6 Month Change

63.88%

Ytd Change

2.18%

1 Year Change

-8.23%

3 Year Change

-2.51%

5 Year Change

138.93%

10 Year Change

-96.25%

Max Change

-99.01%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment